Japanese Patent Case Summary: 2025 (Gyo-Ke) No. 10103 – Intellectual Property High Court (August 10, 2026)
Cell Growth Inhibiting Copolymer for Use in Ophthalmic Implants
Overview
In a lawsuit seeking the rescission of an appeal decision of the JPO on the subject invention relating to a cell growth inhibiting copolymer for use in ophthalmic implants, whether the JPO’s finding (the invention failed to satisfy the support requirement) was valid was at issue. The Court rejected the complaint of the plaintiff, considering that the plaintiff’s argument is groundless and held that the subject invention does not satisfy the support requirement.
▶ Summary of Judgement and Link to Full Text (Japanese)
Main Issues
Whether the appeal decision of the JPO involves unlawfulness in terms of: (1) the appeal board overlooking the possibility that the invention could be derived from common general knowledge, and making an erroneous comprehensive evaluation; and (2) the board confusing and erring in the assessment of biocompatibility (i.e., whether the JPO erred in its determination under Article 36(6)(i) of the Patent Act).
Court Finding
According to the disclosure in the specification of the subject application…as found in the appeal decision, the problem to be solved by the subject invention is to provide a cell growth inhibiting polymer for ophthalmic implants to inhibit the proliferation of native biological cells present on the surface of the ophthalmic implant after ophthalmic implant surgery…
The cell growth inhibiting polymer for ophthalmic implants of the subject invention is obtained by copolymerizing at least one cell growth inhibiting monomer selected from quaternary ammonium salt monomers selected from MDPB, DMAE-CB, MAE-DB, MAE-HB, and IDMA-1…and at least one other monomer selected from acrylic monomers, silicone monomers, vinyl monomers, and collagen monomers… Satisfying the support requirement requires that a person skilled in the art recognize that, in light of the disclosure in the detailed description of the invention of the subject application or common general knowledge at the time of filing, the proliferation of native biological cells present on the surface of the ophthalmic implant is inhibited when the polymer is used for an ophthalmic implant.
While the disclosure clarifies that among monomers of the subject application, MDPB has been used to reduce the risk of dental caries when copolymerized with dental adhesives and dental resins and that MDPB has also been shown to inhibit mammalian cellular growth…; however, there is no description as to what kind of action based on what kind of property of MDPB reduces the “risk of dental caries” or “inhibits the mammalian cellular growth“.
Furthermore, while it is stated that another example of a quaternary ammonium-based monomer is DMAE-CB…, no description is found regarding what kind of action based on what kind of property of DMAE-CB is related to cell growth inhibiting properties… The detailed description of the invention does not include any description regarding MAE-DB, MAE-HB, and IDMA-1.
In addition, there is no disclosure that a polymer obtained by copolymerizing one monomer selected from the claimed monomers and another monomer inhibits the proliferation of native biological cells present on the surface of an ophthalmic implant when used for such an implant, nor are there any experimental examples or the like supporting this. Even upon examining all the evidence in this case, it cannot be recognized that such common general knowledge existed.
Accordingly, in light of the disclosure in the detailed description of the invention of the subject application or the common general knowledge at the time of filing, what the skilled person would have recognized is merely that MDPB, a specific compound that belongs to the broad compound group of quaternary ammonium salt monomers, possesses an action of inhibiting the proliferation of mammalian cells. The skilled person would not have recognized that when a polymer obtained by copolymerizing one cell growth inhibiting monomer selected from the five types of specific quaternary ammonium salt monomers (the claimed monomers) with one of the four types of other monomers is used for an ophthalmic implant, the proliferation of native biological cells present on the surface of the implant would be inhibited.
Even assuming that the common general knowledge asserted by the plaintiff were recognizable, what would be understood from such knowledge is merely the fact that a compound having a quaternary ammonium group exerts a mechanism of action that inhibits the proliferation of mammalian cells, and the skilled person would not have recognized how the polymer of the subject invention comprising the claimed monomer actually inhibits the proliferation of native biological cells present on the surface after ophthalmic implant surgery. Specifically, it has been known that the action of quaternary ammonium compounds on cells is not determined solely by having a cationic center structure, but is also influenced by hydrophobic structures, ester structures, and the like (Defendant’s Exhibit 1). Moreover, since the composition of cell membranes varies depending on the type of cell, sensitivity to quaternary ammonium compounds should also vary. Furthermore, when a specific quaternary ammonium salt monomer is copolymerized with other monomers, unlike free monomers, it is immobilized in the polymer, and only those present on the polymer surface can exert an action on cells. For these reasons, the degree of action on cells cannot be predicted without experimental confirmation.
Comments
In this judgement, the Court applied the legal standard established by the Grand Panel decision regarding the support requirement, and held as follows:
For an invention of a copolymer having claim features including intended uses and properties, wherein monomers are selected from two lists (a list of cell growth inhibiting monomers and a list of other monomers), the Court pointed out that: (i) various factors affect the cellular action of quaternary ammonium compounds; (ii) sensitivity to quaternary ammonium compounds varies depending on the type of target cell; and (iii) when a specific quaternary ammonium salt monomer is copolymerized with other monomers, unlike free monomers, it is immobilized in the polymer and only those on the polymer surface can act on cells. It is noteworthy that the Court articulated these specific reasons why the degree of cellular action cannot be predicted without experimental confirmation, rather than merely relying on the general unpredictability inherent in chemical inventions.
Given that the subject specification contained only conceptual embodiments and schematic drawings of the polymer structures without a single working example, and that there was no common general knowledge suggesting the solution to the problem, the Court’s determination on the support requirement is considered reasonable.
Nonetheless, the grounds for rescission raised by the plaintiff contain important issues over: i) an erroneous framework of judgement regarding the support requirement (the plaintiff asserted that individual experimental data is unnecessary across different target cells if they have a common mechanism of action, which is established as common general knowledge); and ii) an erroneous judgement and confusion regarding biocompatibility (the plaintiff argued that the appeal decision confused the support requirement and a separate framework of judgement of biocompatibility to overlook the purpose of the Patent Act to protect technical ideas, and misunderstood the technical feature (immobilization structure, mode of action) of the subject application).
That is, if a certain mechanism of action regarding cell growth inhibition on ophthalmic implants had been explained in the specification, working examples might not have been mandatory. Furthermore, a certain level of reasonableness is found in the plaintiff’s argument that “cell growth inhibition” in the subject invention is a broad concept including the reduction of proliferation rate and inhibition of adhesion rather than necrotic cell death, and that because the quaternary ammonium salt monomer of the subject invention is immobilized in the polymer through copolymerization and does not elute, its mode of action fundamentally differs from free quaternary ammonium compounds such as benzalkonium chloride.
Techniques of “to either coat or covalently bond cell growth inhibiting chemicals to the surface of the implant” and “to infuse the polymer of the ophthalmic implant with a cell growth inhibiting metal ion” (the diffusion of the metal ion out of the polymer can be toxic) are cited as prior art. In contrast, the subject invention provides a technical idea with means of solution of and effect of the following: “[B]ecause the entire co-polymer, not just the surface of the co-polymer, has cell growth inhibiting properties, ophthalmic implants made from this type of co-polymer will not lose their cell growth inhibiting properties even if the surface of the implant becomes eroded over time”. The subject Court finding suggests that even if such a technical idea is understandable, it remains difficult to overcome a rejection for lack of support requirement without at least minimal supporting experimental results.
Subject invention:
“A cell growth inhibiting polymer for use in an ophthalmic implant obtained by copolymerizing:
at least one cell growth inhibiting monomer; and
at least one other monomer selected from an acrylic monomer, a silicone monomer, a vinyl monomer and/or a collagen monomer,
wherein the at least one cell growth inhibiting monomer is a quaternary ammonium salt monomer, and the quaternary ammonium salt monomer is selected from methacryloyloxydodecylpyridinium bromide (MDPB)…, thereby inhibiting the proliferation of native biological cells present on the surface of the ophthalmic implant.”
Satoki SERA